C
rohn's disease (CD), a chronic inflammatory condition of unknown etiology, may involve the small bowel, the colon, or both. 1 Some patients may have predominantly nonperforating nonstricturing (inflammatory) disease, whereas others have or may develop a perforating (fistulizing) or stenotic (stricturing) phenotype. 2, 3 The subgroup of patients who develop perianal CD can experience significant morbidity, including perianal pain, scarring, fecal seepage, and fecal incontinence. [4] [5] [6] [7] Perianal fistulas are the most common type of external fistula; less common external fistulas include enterocutaneous and rectovaginal. Perianal CD is not uncommon; several population-based studies have estimated the incidence of perianal fistulas in patients with CD to range from 14% to 43%, with referral center studies tending to have higher estimates than population-based studies. 4, [8] [9] [10] [11] [12] In an early population-based epidemiologic study in the United States, the cumulative incidence of perinanal fistulas was 33% during the 10 years after CD diagnosis and 50% after 20 years. 4 Effective options for treating patients with perianal fistulizing CD include biologics and/or examination under anesthesia (EUA) with seton drainage procedures. [12] [13] [14] [15] [16] [17] [18] In a population-based study conducted before the anti-tumor necrosis factor (anti-TNF) era, the majority of patients required at least 1 disease-related operation because of the morbidity associated with perianal fistulizing CD and nearly one-third required a major surgery, including proctectomy, proctocolectomy, or diverting ileostomy. 4 The introduction of anti-TNF therapy has revolutionized the treatment of perianal fistulas in CD, with initial fistula healing rates of 68%. 13, 14 Subsequent trials that assessed the maintenance of fistula closure throughout a 6-to 12-month period using anti-TNF agents found the maintenance of fistula closure with these agents in clinical trials to be from 30% to 40%. [14] [15] [16] [17] One hypothesis for why anti-TNF agents are not more effective for maintaining fistula closure is that these agents lead to rapid closure of the cutaneous fistula openings and subsequent formation of perianal abscesses or recurrent fistulas when a seton is not in place to promote drainage and control healing. The rate of abscess formation was 11% in the initial infliximab study, 15% in the infliximab fistula maintenance study (ACCENT II trial), and 11% in the 56-week CHARM fistula analysis. 13, 14, 16 This hypothesis is supported by small retrospective studies that demonstrated that the durable fistula healing rate could be improved by establishing drainage and controlling fistula healing before beginning medical treatment. 19, 20 Despite these findings, there is a lack of agreement as to whether EUA is needed before beginning anti-TNF therapy for the treatment of CD-related perianal fistulas. American Gastroenterological Association guidelines for the treatment of CD do not include recommendations for the management of fistula, 21 whereas other guidelines recommend combined medical and surgical treatment of symptomatic fistula. [22] [23] [24] Although guidelines suggest that setons be placed before initiation of anti-TNF therapy, these recommendations are supported largely by studies with small study populations. 19, 20, 23, 24 The purpose of the present study was to examine the hospital-related cost-benefit of seton placement before initiation of an anti-TNF agent among patients with perianal CD in a large claims database.
METHODS

Data Source
Patient-level data were extracted from the Truven Health MarketScan Commercial Claims and Encounters Database. 25 The MarketScan database captures person-specific health care use; expenditures; and enrollment in inpatient, outpatient, and prescription-drug services for millions of beneficiaries residing in multiple states across the United States. Data from individual patients are integrated from all providers of care, maintaining all health care utilization and cost connections at the patient level. In compliance with the Health Insurance Portability and Accountability Act of 1996, the database consists of fully de-identified data sets, with synthetic identifiers applied to patient-level and provider-level data to protect the identities of both the patients and data contributors.
Study Population
Patients ($18 years of age) diagnosed with CD (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code: 555.xx) and anal fistula (ICD-9-CM code: 565.1) who initiated biological therapy after both the CD and fistula diagnoses were identified between January 1, 2006, and March 31, 2015 from the MarketScan database and included in the study population. The first identified treatment with biologics to occur after diagnoses of CD and fistula was designated the index event with the associated date selected as the index date. Treatment with biologics approved for the treatment of CD in the United States at the time this analysis was initiated (adalimumab, certolizumab, and infliximab) was identified by corresponding the National Drug Codes and Current Procedural Terminology (CPT) codes. Further inclusion criteria in the study population required that all patients had 6 months of continuous medical and prescription benefit coverage before (baseline period) and after (follow-up period) the index event to ensure all patients had complete claim records. Patients who had a seton procedure, identified by CPT codes during the baseline period, were grouped into the seton before biological (SBB) treatment cohort. Patients who did not have a seton procedure during the baseline period were grouped into the no seton before biological (NSBB) treatment cohort.
Evaluation of Baseline Demographics and Clinical Characteristics
Patient demographics consisting of age, sex, US region of residence, and health plan type and clinical characteristics consisting of CD location, baseline drug use (antibiotics, immunosuppressants, steroids, and 5-aminosalicylic acid), DeyoCharlson Comorbidity Index (DCCI), and comorbidities were determined for all patients in the SBB and NSBB study cohorts. The DCCI is a widely used measurement that is predictive of the likelihood of 1-year and 10-year mortality based on the presence or absence of 19 comorbid conditions and their associated assigned weights. 26 
Hospitalization and Cost Comparisons
The number of hospitalizations for any reason (all-cause [AC]) and the number that was fistula related, which included all inpatient discharge claims with either a primary or nonprimary ICD-9-CM code for anal fistula, were evaluated for each patient in the study cohorts during the 6-month baseline and follow-up periods. The total associated hospitalization costs evaluated included payments made to the hospital and the physician(s) during hospitalization. The cost of seton placement was included within the baseline costs for patients within the SBB cohort because the procedure occurs before the index biological treatment. The mean number of hospitalizations and the associated total mean costs during the baseline and follow-up periods were then compared between the SBB and NSBB study cohorts. In addition, mean differences in the number of hospitalizations, both AC and fistula related, and associated costs between the follow-up period and baseline period were determined and compared between study cohorts.
Statistical Analyses
Descriptive statistics were used to summarize and compare the demographic and clinical characteristics of the study cohorts. Mean, SDs, and medians are reported for continuous data, and counts and percentages are reported for categorical data. For comparisons of unadjusted AC and fistula-related (FR) hospitalizations and associated costs between the SBB and NSBB cohorts, chi-square tests and t tests were used for categorical and continuous variables, respectively. Generalized linear models with adjustment for key patient demographic and clinical characteristics were also performed for comparisons of AC and FR hospitalization counts and total hospitalization costs between cohorts. The covariates included in the regression models were age; sex; US region of residence; DCCI score; CD location; baseline use of antibiotics, immunosuppressants, steroids, and 5-aminosalicylic acid; and baseline comorbidities, including diabetes, hypertension, and asthma. A critical value of 0.05 was used to determine statistical significance. All statistical analyses were performed using SAS 9.4. 27 
RESULTS
Study Population
Between January 1, 2006, and March 31, 2015, 306,962 patients diagnosed with CD were identified from the MarketScan database. A total of 10,878 (3.5%) patients with CD were also diagnosed with a perianal fistula. Of these patients, 4434 (40.8%) initiated biological therapy after developing perianal CD. The final study population included 1845 patients who were diagnosed with both CD and anal fistula before beginning treatment with biologics and had continuous insurance coverage during the baseline and follow-up periods (Fig. 1) . Among the study population, 326 (17.7%) patients had a seton procedure during the baseline period (SBB cohort) and 1519 did not (NSBB cohort). Adalimumab and infliximab were the index biologics for most patients in both cohorts (Fig. 1) .
Baseline Characteristics
SBB and NSBB study cohorts were similar in age and distributions of age, sex, health plan coverage, and regions of residence (Table 1) . Although comorbidity severity, as measured by DCCI scores, was similar for both study cohorts, significantly greater percentages of patients in the SBB cohort had asthma (5.2% versus 2.8%, P ¼ 0.028) and cardiovascular disease, excluding venous thromboembolism and hypertension (31.0% versus 17.5%, P , 0.001) compared with patients in the NSBB cohort. In addition, significantly more patients included in the SBB cohort used antibiotics (86.5% versus 55.7%, P , 0.001) and 5-aminosalicylic acid (40.2% versus 33.8%, P ¼ 0.029) during the baseline period.
Unadjusted Hospitalization and Cost Comparisons
Before treatment with biologics, the number of AC (0.46 versus 0.35, P ¼ 0.024) and FR (0.19 versus 0.08, P , 0.001) hospitalizations was higher for SBB patients than NSBB patients (Fig. 2) . In addition during the baseline period, costs for FR hospitalizations were higher for those in the SBB cohort in comparison with the NSBB cohort ($3819 versus $2,155, P ¼ 0.012). During the follow-up period, SBB patients had a lower mean number of AC (0.23 versus 0.41, P , 0.001) and FR hospitalizations (0.07 versus 0.16, P , 0.001) compared with NSBB patients (Fig. 2) . Mean total hospitalization costs incurred during the follow-up period were consequently lower for the SBB cohort in comparison with the NSBB cohort (AC: $5514 versus $9,711, P ¼ 0.019; FR: $1900 versus $4,156, P ¼ 0.010) (Fig. 3) . FR hospitalization costs represented approximately 34% and 43% of total hospitalization costs for all causes for the SBB and NSBB cohorts, respectively. Significant differences in AC and FR inpatient resource utilization from follow-up to baseline were also observed ( Table 2) . For SBB patients, the mean number of AC (20.23 versus 0.05, P , 0.001) and FR hospitalizations (20.13 versus 0.08, P , 0.001) as well as associated hospital costs (AC: 2$2228 versus $2,099, P ¼ 0.030; FR: 2$1920 versus $2,000, P , 0.001) declined during the followup period in comparison with the baseline period, whereas inpatient resource utilization and costs of NSBB patients increased.
Adjusted Hospitalization and Cost Comparisons
After adjustment for key patient characteristics, SBB was associated with a significant reduction in the number of AC hospitalizations (20.19, P , 0.001) and associated total costs (2$4,188, P ¼ 0.021) and FR hospitalizations (20.10, P , 0.001) and associated total cost (2$2,469, P ¼ 0.006) compared with NSBB during the follow-up period (Table 3) . 
DISCUSSION
The present study demonstrated the hospital-related costbenefit of seton placement before initiation of an anti-TNF agent in patients with perianal CD. Based on the hypothesis that combined biological and surgical treatment of perianal CD is more effective than biological therapy alone, the present study compared health care utilization and costs for patients with perianal CD who had seton placement before initiating biological therapy versus those who did not have a seton procedure before biological initiating therapy. The cohorts were well matched with respect to baseline characteristics, most comorbidities, and concomitant therapy other than antibiotics. Analysis of health care utilization and the associated costs revealed that patients in the SBB cohort had fewer AC and FR hospitalizations and incurred lower health care costs compared with the NSBB cohort. Similar results were obtained after adjusting for baseline characteristics and prescription drug use, suggesting that there is a real benefit of EUA and seton placement before starting patients on anti-TNF therapy. Because it is possible that patients could be admitted with a perianal abscess requiring drainage and that fistula is not coded on their hospitalization discharge records, we have also performed a sensitivity analysis to assess the number of patients with hospitalizations of perianal abscess, but without hospitalizations of perianal disease/fistula in the follow-up period. The percentage of patients with perianal abscess hospitalizations, but not perianal disease in the follow-up periods were similar, with 2.5% versus 2.9% among the SBB and NSBB cohort (P ¼ 0.66). The number of such hospitalizations of perianal abscess was numerically lower among the SBB cohort, but did not reach statistical significance, and thus is not likely to have a major impact on the current study results. In this study, the SBB and NSBB cohorts also differed in the number and costs of hospitalizations before treatment with biologics. These differences may be attributed to the patients in the SBB cohort being more likely to receive a seton due to having more severe perianal disease, which also may explain their greater use of antibiotics before receiving biologics.
Seton placement is felt to improve fistula healing for several reasons. Because persistent sepsis within the fistula tract can impede effective healing with medical treatment, many patients will benefit from placement of setons to establish drainage and control healing. In addition, because the internal and external openings of a fistula track are abnormal openings, there is a tendency for premature closure of the cutaneous openings of the fistula track thus leading to abscess formation or additional ramification of the fistula. This is even further accelerated by the use of an anti-TNF agent. The placement of a seton helps to maintain fistula drainage until the track becomes inactive on medical treatment.
The findings from this study are corroborated by previous retrospective studies, suggesting that the durable fistula healing rate could be improved by establishing drainage and controlling fistula healing before beginning medical treatment. 19, 20 In a study by Regueiro and Mardini, 19 patients in whom an EUA with seton placement and drainage was performed were significantly less likely to have a recurrence of their fistula compared with those who never had surgical drainage established (44% versus 79%). Similarly, in the series by Topstad et al, 20 the authors reported a 69% complete fistula response rate in a small number of patients treated with combination surgical and medical therapy. The Vanderbilt IBD Center has demonstrated both in a retrospective study of 21 patients and in a small prospective study of 10 patients with perianal fistulas that performing EUA before the initiation of anti-TNF therapy prevents abscess formation during treatment and improves long-term fistula healing. 28, 29 More recently, El-Gazzaz et al 18 reported better fistula outcomes for patients receiving surgery followed by anti-TNF therapy compared with those who underwent surgery alone.
In the absence of large-scale randomized controlled trials, evidence from a retrospective case series, observational studies, and small prospective studies supports the use of image guidance and seton placement in conjunction with biological therapy in adults with perianal fistulas. [18] [19] [20] [28] [29] [30] In addition, combining seton drainage with infliximab therapy recently has been shown to be effective for treating complex perianal fistulas in pediatric patients with CD. 31 As exploration of optimal fistula management strategies continues to evolve, serial imaging or EUA could be used to guide the duration of biological therapy required to reduce inflammation and timing of subsequent seton removal. 30 Moreover, education regarding the use of EUA/seton placement before initiating biological therapy is warranted, as a survey study investigating differences in CD management between community-based gastroenterologists and CD specialists reported that community-based providers were less likely than specialists to send a patient for an imaging study and EUA before starting an anti-TNF agent for perianal fistulas. 32 Assessments of medical costs and utilization associated with different approaches for treatment of perianal CD are limited. Available data reveal increased health care utilization and higher costs of care for patients with perianal fistula compared with other disease phenotypes. Data from the European Collaborative Study Group of Inflammatory Bowel Disease demonstrated that phenotype drives health care costs in CD; the subset of patients with penetrating disease plus perianal fistula incurred greater costs for total care, diagnosis, and drugs compared with other phenotypes, including patients with penetrating disease but no perianal fistula. 33 In addition, costs associated with surgical hospitalization were greater for perianal disease versus other phenotypes, except for penetrating disease without fistula. 33 A comparison of health care costs in CD patients with and without fistula found median paid claims per patient were $10,863 in the fistula cohort and $6268 in the nonfistula cohort, and the difference was driven mainly by higher hospital and surgery costs in patients with fistula. 34 A study in Spain concluded that biological therapy is the main cost driver in complex perianal CD, with costs for surgery and hospitalization representing a much smaller proportion, presumably resulting from the effectiveness of biologics in this population. 35 Although the effectiveness of biological therapy may have decreased the need for subsequent surgical intervention, the current study findings suggest that having a seton procedure before initiating biological therapy results in fewer FR hospitalizations and further cost reductions. These findings may be helpful for providers for identifying high-risk patients for hospitalizations, optimizing treatment strategies, and providing value-based care to patients with perianal CD. 36, 37 Limitations of this observational study include that specific patient data, such as smoking history, ethnicity, disease phenotype and severity, location, or type of fistula were not available for the majority of patients and that biological agents other than adalimumab, infliximab, and certolizumab are now approved for CD. The sample represents the commercially insured population in the United States and may not be representative of all patients with perianal CD who are being treated with biologics. A substantial portion of the MarketScan database consists of patients from the Southern region and may result in a disproportionate representation of the treatment practices from the South region in the United States and thus limit generalizability. In addition, only 13% of the CD population had seton placement, which is considerably lower than the approximately 60% reported from referral centers 18, 38 but is an accurate reflection of what occurs in general practice and comparable with the 10% reported in the National Surgical Quality Improvement Program database. 39 Although other studies have reported a more durable response to combined seton and biological therapy for patients with complex versus simple fistulas, 19 we could not evaluate differences in costs because these subgroups could not be identified in the database. In addition, the focus of this study was to provide an evaluation of hospitalizations among study cohorts in the follow-up period, and the exact number of operative procedures during hospitalizations could not be reliably ascertained based on the information in the claims database, neither did the study follow patients in the outpatient setting. Because all patients in the study were required to have continuous insurance coverage during the baseline and follow-up periods, this may have introduced some bias in that selected patients for the study may have been from a higher socio-economic group. However, this is a common approach of such retrospective database claims analyses to ensure all patients have complete baseline period claim records. 34, 40, 41 Finally, the database did not allow for assessment of fistula outcomes, so it is unknown whether the differences in hospitalization rates and associated costs were related to the index fistula event or subsequent recurrence.
In conclusion, patients with perianal CD who had a seton placed before treatment with biologics used fewer health care resources and incurred lower health care costs compared with those who did not have the seton procedure. The present analysis adds to the current body of evidence in support of seton placement in conjunction with biological therapy in adults with perianal or intestinal fistulas; however, the effectiveness of this treatment approach has yet to be confirmed in randomized controlled trials. 
